Introduction: A gap between evidence-based recommendations for prescribing antipsychotics and its implementation in practice could be overcome by local guidelines. Aim: The aim of our study was to locally adapt the national guideline for schizophrenia and evaluate its impact on prescribing practice as well as on clinical and humanistic outcomes in a long-stay psychiatric hospital Dobrota in Kotor, Montenegro. Subjects and Methods: This was academic, prospective, IV phase interventional study, which measured outcome before and after investigators intervention within healthcare system. The study was conducted in two six-months phases separated by implementation of the local guidelines. Prescribing practices and treatment outcomes were monitored in both phases of the study. Results: Study included 111 patients. Although the guidelines did not infl uence total volume of prescribed antipsychotics, social functioning and environmental aspects of quality of life were improved. Conclusions: Writing and adopting the guidelines for local use might be associated with some benefi t in humanistic outcomes, but multi-faceted intervention should be considered in order to achieve more substantial impact on prescribing practices and clinical outcomes.
INTRODUCTION
Main focus of the multidisciplinary treatment of mental illnesses, especially schizophrenia, is still on the pharmacological therapy in majority of settings [1] . It might be, partly, justifi ed, by the increasing availability of newly identifi ed drugs with improved effi cacy, safety, and tolerability profi les (e.g., atypical antipsychotics, selective serotonin reuptake inhibitors, alternative mood-stabilizing agents).
Nevertheless, relative cost and complexity of the neuropsychopharmacology advancements have also been emphasised [1, 2] . Th is rendered publication of numerous treatment guidelines and practice recommendation, aiming at best scientifi c evidence being translated into practice, for improving clini-cal, humanistic and economic outcomes of treatment for patients with mental disorders. [1, [3] [4] [5] [6] [7] [8] [9] [10] . Although it is recognized that appropriate prescribing could improve patient outcomes and cut the expenses [1, 11] , there is a gap between evidence based recommendations and their implementation in local practices, especially in developing countries [1, [12] [13] [14] [15] . Several barriers were identifi ed in developing countries that adversely aff ect implementation of evidence-based guidelines in clinical practice (lack of evidence-based healthcare system [16] , lack of political support [16] , lack of knowledge and appropriate training of physicians [17] , etc.), but still we are far from complete insight into the problem, partially due to social and cultural diff erences across the countries.
In 2012, the Ministry of Health of Montenegro issued the fi rst National guideline for the treatment of Schizophrenia [7] . Consistent with other guidelines and research fi ndings [2, 13, 18] antipsychotic polypharmacy (APP) was not supported; advantages of efficacy/tolerability profi les of second-generation antipsychotics (SGA) and eff ectiveness of clozapine augmentation for treatment resistant patients were elaborated. However, national guidelines did not cover issues such as treatment of chronic schizophrenia patients resistant even to clozapine, treatment of adverse eff ects of antipsychotics, or optimal dosing regimens.
AIM
Th e aim of our study was to locally adapt the national guideline for schizophrenia and evaluate its impact on prescribing practice as well as on clinical and humanistic outcomes in hospital patients with severe mental illnesses in Montenegro.
SUBJECTS AND METHODS

Subjects with ethical considerations and informed consent
Th is academic, prospective, IV phase, interventional study, which measured outcome before and aft er intervention -adaptation and application the national guideline for schizophrenia, was conducted at specialized psychiatric hospital Dobrota in Kotor, Montenegro. Th e Ethics approval for the study was obtained from the Ethics Committee of Clinical Center of Montenegro, Podgorica (No 03/01-11941/1), and from the Ethics Committee of Dobrota hospital .
Th is is a 241-bed, non-research facility for patients with severe mental illnesses, with 141 beds for long term patients. Th e study was conducted during the period from June the 15 th , 2012, to June the 15 th , 2013. All chronic patients of this facility (hospitalized for more than 6 months) with the diagnosis of schizophrenia (F20.0-F20.9) were included in the study, except for the patients with concomitant mental retardation or impairment of consciousness.
Methods
Th e intervention consisted of development, adoption and implementation of local guideline for pharmacological treatment of schizophrenia in Dobrota hospital. Th e study had two phases separated by adoption and implementation of the local guideline: the fi rst, sixmonth phase, when baseline prescribing practice in the hospital was monitored, and the second six-months phase, aft er the guideline were adopted and implemented, when eff ects of the guidelines to prescribing practice were observed. Th e guideline was developed initially by an independent expert, and then further refi ned and adopted by the Expert Board of the Dobrota hospital (composed of psychiatrists), aft er discussion with all other employed psychiatrists and taking into account their feedback.
All study variables were measured at the end of the respective study phase. Th e demographic data collected included: age, sex, duration of illness, duration of current hospitalization, type of hospitalization (continuous or interrupted during weekends), psychiatric and other diagnosis. Data about medications, laboratory monitoring and adverse reactions were also collected.
Clinical and humanistic outcomes of the intervention (implementation of local treatment guidelines) -were assessed using standardized rating scales: (1)18-item Brief Psychiatric Rating Scale-BPRS to evaluate clinical status [19] ; (2)Th e Abnormal Involuntary Movement Scale-AIMS was used for assessing occurrence and severity of dyskinesias [20] ; (3)Humanistic outcomes were assessed using Euroqol (Serbia (Serbian) EQ-5D-5L) and WHOQOL (WHOQOL BREF_Serb_Cro-at_Bosnian). Th e BPRS and AIMS are scales in the public domain, while permissions for use of EQ-5D-5L and WHOQOL BREF were obtained from copyright holders.
Statistical analysis
Th e study data were statistically described by means and standard deviations (for continuous variables) or percentages (for categorical variables). Th e diff erences between values of continuous study variables before and aft er the intervention were tested by Student's Ttest for large, dependent groups, when the values were normally distributed (as tested by Kolmogorov-Smirnov test), and by Wilcoxon's test, when the values were not normally distributed. Th e diff erences between values of categorical variables before and aft er the intervention were tested by Chi-square test. Th e diff erences were considered signifi cant if probability of null hypothesis was less than 0.05.
RESULTS
Study included 111 subjects. Demographic characteristics and diagnosis are presented in the Patient-perceived quality of life on EUROQOL 5D 5L visual analogue scale was 53.6% (± 26.2), and WHOQOL BREF scores in the fi rst phase of the study for the four domains: physical health, psychological, social relationships and environment are presented in the Table 2 .
Antipsychotics were prescribed to 108 of 111 patients, at the median daily dose expressed as chlorpromazine equivalent of 546 mg, ranging from 50 to 2600 mg. Th e fi rst generation antipsychotics (FGA) were prescribed to 85 and the second generation to 74 patients. Most of the patients (69.4%) received combinations of antipsychotics. Antidepressants were co-prescribed to 6 and lithium to 9 patients. Percentages of patients taking anticonvulsants, antiparkinsonian medications and benzodiazepines were: 38.7%, 45% and 58.6%, respectively.
Th e intervention
Th e local guidelines for pharmacological treatment of schizophrenia were developed by an independent expert in clinical pharmacology (from Faculty of Medical Sciences, University of Kragujevac, Serbia), and then discussed and fi nally adopted by the Professional Board of Dobrota hospital at the session held on December 21 st , 2012. Th e local guidelines for treatment of schizophrenia were based on the National guidelines of Montenegro, and then developed further in following areas: treat- 
Phase 2
Th e post hoc therapeutic choices did not demonstrate guideline adherence (Table 3) . Treatment with combinations of antipsychotics increased (75 to 79), but not signifi cantly. However, the median daily dose of antipsychotics expressed as chlorpromazine equivalent increased from 546 mg in the fi rst phase to 572 mg (range from 50 to 2600 mg) in the second study phase (p = 0.016, Z = -2.398). Mean scores on the rating scales, before and aft er the implementation of guidelines, are presented in the Table 4 . Involuntary movements worsened in the second phase of the study, with higher AIMS scores recorded for 63 of 107 patients assessed (Table 4) .
Laboratory analyses revealed increase of the blood glucose level Th ere were no signifi cant diff erences in mean BPRS scores, as well as estimated severity of illness (Table 4) .
Patient-perception of quality of life assessed by EUROQOL 5D 5L visual analog scale, as well as physical health or psychical [28] . Th e extent of APP observed in our study (69.4% to 73.1%), was not frequent in the recent literature. Although acknowledging geographical variations (Asia: median = 32%, Europe: median = 23%, North America: median = 16%, and Oceania: median = 16.4%.), a systematic review Galllego [26] found global median of 19.5% of patients receiving APP. It is also reported that combination treatment occurs between 3% and 71%, with mostly recorded prevalence rates of between 10% and 30% [28] . Th ere are some distinctive features of our study settings that have been described in the literature as correlated with the high extent of APP prescribing. Variables such as: non-teaching hospital settings, less research involvement [29] , FGA prescribing, duration of the disease, in patient treatment [30] [31] [32] , longer inpatient stay [25, 27] , are found to be associated with higher rates of APP prescribing. Although its effi cacy/safety profi le is not evidence based, APP is oft en advocated in the literature with greater illness severity, complexity, chronicity, and refractoriness [27] , which are all characteristics of patients in our study.
Median daily dose of antipsychotics signifi cantly increased during the study: from 546 to 572 mg of CPZ equivalent. Although close to the upper limit, the median dose remained within the recommended range (300-600 mg of CPZ equivalent), but the prescribed daily doses showed considerably large amplitude from 50 to 2600 mg of CPZ equivalent. Previously published studies consistently showed relation between APP and greater total antipsychotic dose [27, 29, [34] [35] [36] . In addition, it was recorded that patients treated in the specialized psychiatric facilities were frequently overdosed in comparison with recommendations [37] . Increasing the dose may not necessarily indicate poor quality care, and may be appropriate for non-responders to lower doses. Th e reasoning is mostly based on the diff erences between patients who fulfi ll stringent criteria for inclusion in pivotal randomized controlled trials (RCTs) on which dosing recommendations are usually based, and real life settings [37, 38] .
Th ere is lack of reported psychopacondition assessed by WHOQOL BREF questionnaire did not signifi cantly change from baseline aft er adoption of the local guideline. However, quality of life of the patients concerning social and environmental domains signifi cantly improved aft er adoption of the guideline (Table 4) .
DISCUSSION
Overall, the study showed that adoption of local guideline did not signifi cantly alter prescribing patterns. Antipsychotic polypharmacy remained routinely used with FGAs as prevailing treatment choice and the daily dose in CPZ equivalents has signifi cantly increased. Such result is not surprising, since diff ering adherence to psychiatric guidelines is documented worldwide [13, 15] . Broekema [13] in European pharmaco-epidemiological study, carried out at 45 hospitals in six western European countries, implied that "more than half (52.9%) of the patients are not being treated according to the psychiatric handbooks and guidelines". In Canadian schizophrenia treatment services [21] conformance with pharmacological guideline recommendations ranged between 58% and 90%. Th is fi nding of our study could have been anticipated, since it is recognized that well-designed multifaceted interventions are needed for improving adherence to guideline recommendations [12, 22, 23] . In Montenegro the fi rst National schizophrenia guideline was published shortly before the study onset (in June 2012), with, to our knowledge, no evidence based supporting interventions for augmenting implementation. Observed guideline non-adherence could be further elaborated within the Cabana's [24] conceptual framework, explaining that before external research evidences (i.e. guidelines) can aff ect patient outcomes, it fi rst aff ect physician knowledge, then attitudes, and fi nally behavior.
Antipsychotic polypharmacy did not decrease aft er the guideline adoption comparing with baseline. Several other studies have shown that patients receiving APP before the intervention were more likely to receive it at the study end point as well [25] [26] [27] . Th is phenomenon is not characteristic only for the developing countries, and the trend of not decreasing APP is commonly observed in long term studies from North America and Europe, both in national and local settings [28] . APP Iličković IM: Eff ects of Local Guidelines on Prescribing Practice and Treatment Outcomes in a Long-Stay Psychiatric Facility thology ratings or adverse eff ects in APP studies, and our study adds value to this, "underresearched area" [28] . Th e results of BPRS scale consistently revealed no improvement in clinical outcomes. Bearing in mind lack of signifi cant changes in prescribing habits aft er adoption of the guidelines, these fi ndings were expected. Th e observed increase in daily dose did not have positive impact on clinical outcomes, and it could be associated with significantly higher score on the AIMS scale. Higher total daily antipsychotic dosing together with extensive FGA prescribing and APP could predispose worsening of involuntary movements. However, there were some positive eff ects of the intervention on the humanistic outcomes, as shown by WHOQOL scale in social and environmental domains.
Th e limitation of our study is its single-center character resulting from the fact that Dobrota hospital is the only long-stay psychiatric facility in Montenegro. Besides, the study was conducted shortly aft er introduction of concept of national evidence-based guidelines in Montenegro, so culture of using guidelines in general was not developed enough among the physicians. Th e naturalistic setting and sample characteristics obtained using broad inclusion and minimal exclusion criteria, and assessing outcomes using validated scales adds new knowledge about treatment of schizophrenia. Patients with wide age range, extensive period of permanent hospitalization and disease duration, presence of coexisting conditions and co-medications provide context, which is not oft en presented in the literature due to stringent criteria for sampling in randomized controlled trials.
CONCLUSION
From the results of our study it could be concluded that mere writing and adopting the guidelines is not suffi cient to change established prescribing practice in treatment of schizophrenia, or clinical and humanistic outcomes in developing countries with shortlived culture of evidence-based healthcare; much more has to be done on promotion of the guidelines, including research of eff ectiveness of various healthcare interventions.
